Eloralintide vs Efpeglenatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: GSBR-1290, Structure GSBR-1290
Eloralintide (Eli Lilly code LY3841136) is an investigational, long-acting, selective amylin receptor agonist given as a once-weekly subcutaneous injection for obesity. Amylin is the satiety hormone your pancreas releases alongside insulin, and eloralintide is built to mimic it without the gut side effects that sink most appetite drugs. It is not approved anywhere yet, but it has cleared Phase 1 and a 263-person Phase 2 trial with weight loss up to roughly 20 percent, and Lilly has said it is moving into Phase 3.
Also: Eppe, HM11260C
Efpeglenatide is a long-acting, once-weekly GLP-1 agonist from Hanmi Pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. Sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. Hanmi relaunched it for obesity, and on 7 October 2026 South Korea approved it as Eppe, the country's first homegrown GLP-1 obesity drug. It is not approved by the FDA or EMA.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Eloralintide | Efpeglenatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Amylin (also called IAPP) is a hormone co-secreted with insulin after you eat, and it tells your brain you are full and slows how fast your stomach empties. Eloralintide is engineered to selectively switch on the amylin receptor, which is the calcitonin receptor paired with a receptor-activity-modifying protein (RAMP), in appetite-control regions of the brainstem and hypothalamus. The result is reduced food intake and earlier satiety. The reason this class is interesting is that, unlike GLP-1 drugs such as semaglutide and tirzepatide, amylin agonists seem to drive weight loss with much less nausea and vomiting, which is what the eloralintide trials reported. Whether it preserves more lean mass than GLP-1 drugs is a real hypothesis being tested, not a settled fact. | Efpeglenatide activates the GLP-1 receptor, which raises insulin release after meals, lowers glucagon, slows stomach emptying and reduces appetite. The active part is an exendin-4 analog (the same parent peptide as exenatide and lixisenatide) attached through a small linker to a human IgG4 Fc fragment, using Hanmi's LAPSCOVERY platform. The Fc piece makes the molecule big enough to dodge kidney clearance and lets it recycle in the body, which stretches its half-life to weekly dosing. Hanmi argues its lower brain penetration explains the milder GI profile; that is a company argument rather than an independently proven fact. |
| Common Dosing | 120-240mg once daily Once daily | 10 mg once weekly maintenance (Korean label) Once weekly |
| Administration | Oral tablet | Subcutaneous auto-injector once weekly |
| Typical Duration | 36 weeks in Phase 2 trials | Long-term (chronic weight management); 40-64 weeks in the Korean phase 3 |
| Best Time to Take | - | Same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the few research peptides on this site with genuinely strong, recent human data. The Phase 1 proof-of-concept study (Eli Lilly, published 2026) randomized 100 adults with obesity across five ascending dose cohorts and reported dose-proportional pharmacokinetics and least-squares mean weight reductions of 2.6 to 11.3 percent by week 12, with notably low gastrointestinal side effects (nausea 8 percent, vomiting 4 percent). In November 2025 Lilly announced topline Phase 2 results in 263 adults with obesity or overweight: at 48 weeks all dose arms beat placebo, with mean weight loss from about 9.5 percent at the lowest dose up to 20.1 percent at 9 mg, versus 0.4 percent on placebo, plus improvements in waist circumference, blood pressure, lipids, and glycemic markers. The most common adverse events were mild-to-moderate nausea and fatigue. The honest caveat: full peer-reviewed Phase 2 data and any head-to-head against tirzepatide are still pending, and there are no long-term safety or cardiovascular outcome results yet because Phase 3 is only just beginning. So the early efficacy signal is impressive, but durability and long-term safety are unproven. | The strongest data come from Sanofi's AMPLITUDE-O trial (NEJM 2021), which enrolled people with type 2 diabetes and cardiovascular or kidney disease. Efpeglenatide 4 or 6 mg weekly cut major cardiovascular events by 27% versus placebo (7.0% vs 9.2%, hazard ratio 0.73) over a median of 1.8 years, and also reduced kidney outcomes. Sanofi still returned the rights in 2020 for business reasons. Hanmi then ran a Korean phase 3 obesity trial in 448 adults without diabetes (average BMI 32): at 40 weeks, weight loss was 9.02% versus 0.89% on placebo, and 75.1% lost at least 5%. That is less weight loss than semaglutide or tirzepatide in their pivotal trials, though trial designs differ, and GI side effects were somewhat lower (diarrhea 17.6%, nausea 16.6%, vomiting 11.6%). Korea's MFDS approved it for chronic weight management on 7 October 2026, with launch planned for late October. Bottom line: a solid, proven drug class member with real outcome data, but modest weight loss and no Western approval. |
Frequently Asked Questions: Eloralintide vs Efpeglenatide
What is the difference between Eloralintide and Efpeglenatide?
Eloralintide is a weight loss peptide that eloralintide (eli lilly code ly3841136) is an investigational, long-acting, selective amylin receptor agonist given as a once-weekly subcutaneous injection for obesity. amylin is the satiety hormone your pancreas releases alongside insulin, and eloralintide is built to mimic it without the gut side effects that sink most appetite drugs. it is not approved anywhere yet, but it has cleared phase 1 and a 263-person phase 2 trial with weight loss up to roughly 20 percent, and lilly has said it is moving into phase 3. Efpeglenatide is a weight loss peptide that efpeglenatide is a long-acting, once-weekly glp-1 agonist from hanmi pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. hanmi relaunched it for obesity, and on 7 october 2026 south korea approved it as eppe, the country's first homegrown glp-1 obesity drug. it is not approved by the fda or ema. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Eloralintide or Efpeglenatide?
Neither is universally "better" - the choice depends on your specific goals. Eloralintide is typically used for weight loss purposes, while Efpeglenatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Eloralintide and Efpeglenatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Eloralintide and Efpeglenatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.